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ABSTRACT
Mutation-based treatments are a new development
in genetic medicine, in which the nature of the
mutation dictates the therapeutic strategy. Interest
has recently focused on diseases caused by prema-
ture termination codons (PTCs). Drugs inducing
the readthrough of these PTCs restore the produc-
tion of a full-length protein. In this study, we
explored the possibility of using aminoglycoside
antibiotics to induce the production of a full-length
functional p53 protein from a gene carrying a PTC.
We identified a human cancer cell line containing
a PTC, for which high levels of readthrough were ob-
tained in the presence of aminoglycosides. Using
these cells, we demonstrated that aminoglycoside
treatment stabilized the mutant mRNA, which
would otherwise have been degraded by non-
sense-mediated decay, resulting in the production
of a functional full-length p53 protein. Finally, we
showed that aminoglycoside treatment decreased
the viability of cancer cells specifically in the
presence of nonsense-mutated p53 gene. These
results open possibilities of developing promising
treatments of cancers linked with non-sense muta-
tions in tumor suppressor genes. They show that
molecules designed to induce stop-codon
readthrough can be used to inhibit tumor growth
and offer a rational basis for developing new
personalized strategies that could diversify the
existing arsenal of cancer therapies.
INTRODUCTION
A large number of human diseases are caused by prema-
ture termination codons (PTCs) leading to the production
of a truncated protein and mRNA degradation by the
non-sense mediated mRNA decay (NMD) pathway.
Aminoglycoside antibiotics (gentamicin, G418, amikacin)
can bind to mammalian ribosomal RNA, promoting PTC
readthrough and inducing the partial restoration of
full-length protein synthesis. This has been demonstrated
both in cultured mammalian cells (1) and in animal
models. The considerable potential of this approach was
ﬁrst demonstrated in vivo by the work of Barton-Davis
et al. (2) who reported the restoration of dystrophin
levels to 10–20% of normal levels in the skeletal muscle
of mdx mice, following subcutaneous injections of
gentamicin.
Bedwell and coworkers have also shown that G418 and
gentamicin can restore the expression of the cystic ﬁbrosis
transmembrane conductance regulator (CFTR) in a bron-
chial cell line carrying a non-sense mutation in the CFTR
gene (3). In the last few years, this therapeutic strategy has
been studied in hereditary genetic diseases, such as cystic
ﬁbrosis (CF) and muscular dystrophies (4,5) and several
clinical trials have already been performed (6–10). A
recent clinical trial in CF patients showed that the paren-
teral administration of gentamicin at a dose previously
demonstrated to be safe has beneﬁcial clinical effects
and that there is a correlation between the level of
readthrough level and improvements in the clinical state
of the patients (11).
In this study, we investigated the possibility of extend-
ing this approach to cancer treatment. Many cancers are
linked to the presence of a PTC in a tumor suppressor
gene, resulting in the synthesis of a truncated protein
unable to inhibit cell proliferation or promote apoptosis.
We focused on the p53 tumor suppressor gene, which is
mutated in >50% of human cancers, and for which 8% of
all the mutations identiﬁed to date are non-sense muta-
tions. p53 is the cellular gatekeeper for growth and
division. It acts as a transcription factor and triggers
cell-cycle arrest and apoptosis in response to diverse
cellular stresses, including DNA damage, oncogene acti-
vation and hypoxia (12,13). Most of the drugs currently
used to treat cancer patients are genotoxic agents that
exert their anti-tumor activity at least partly by
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conventional radiotherapy and chemotherapy are often
associated with mutant p53 status (14–16). Moreover, it
has been shown that the reintroduction of wild-type p53
into cancer cells lacking p53 actually promotes the repres-
sion of cell growth (17,18) or the induction of apoptosis
(19). The re-expression of functional p53 in cancer cells
may thus lead to a synergistic effect with genotoxic
anti-tumor drugs (14). Gene therapy has been studied in
preclinical settings, in which impressive anticancer activity
has been reported (20,21). However, gene therapy
approaches are limited by the lack of efﬁcient and safe
delivery systems and by the immune response directed
against viral vectors.
Direct targeting and rescue of the endogenous mutated
tumor suppressor is an interesting alternative. Promising
results have been obtained for mutant p53 carrying amino
acid substitutions. In this approach, small molecules or
synthetic peptides were used to restore the active conform-
ation and DNA binding, resulting in an inhibition of cell
growth (22–25). One of these small molecules, PRIMA-1,
when used in combination with adriamycin, strengthened
the effect of adriamycin, triggering an apoptotic response
in non–small cell lung cancer cells (26). PRIMA-1 also
inhibited tumor cell growth in vivo in mice carrying
endogenous missense mutations in p53 (27). These
results strongly suggest that forcing the protein synthesis
machinery to read through a PTC present in a mutant p53
mRNA would interfere with cancer development through
a direct effect on cell proliferation or apoptosis.
The present study was designed to evaluate this
possibility. We ﬁrst quantiﬁed readthrough levels in a
dual reporter assay described in a previous study and
shown to reﬂect the readthrough levels obtained in vivo
(28).Three mutations displaying high levels of induced
readthrough level were retained for further analysis. We
showed that aminoglycoside treatment strongly and
speciﬁcally stabilized mutant p53 mRNAs that would
otherwise be subject to NMD. Moreover, aminoglycoside
treatment resulted in the production of a full-length p53
protein, and this effect was dose-dependent. We further
demonstrated the recovery of transactivation activities
by the re-expressed proteins. Consistent with these
ﬁndings, aminoglycoside treatment reduced the viability
of cultured cancer cells, speciﬁcally in the presence of
non-sense-mutated p53 gene.
MATERIALS AND METHODS
Cell lines and cell culture
All cells were cultured in DMEM plus GlutaMAX
(Invitrogen), except for H1299 cells, which were cultured
in RPMI plus GlutaMAX (Invitrogen). The medium was
supplemented with 10% fetal calf serum (FCS, Invitrogen)
and 100U/ml penicillin/streptomycin. Cells were kept in a
humidiﬁed atmosphere containing 5.5% CO2,a t3 7  C.
NIH3T3 cells are embryonic mouse ﬁbroblasts. H1299 is
p53-null cell line established from a human lung carcin-
oma (provided by ATCC). HDQ-P1 is homozygous for
the non-sense mutation at codon 213 (CGA!TGA) in
the p53 gene. This cell line was established from a
human primary breast carcinoma (29) and was provided
by the German Collection of microorganisms and Cell
Cultures, DSMZ. LoVo (WT p53 and APC R1114X and
del 1bp 1430) and DLD-1 (S241F p53) cells are epithelial
cells derived from a human colorectal adenocarcinoma.
Readthrough quantiﬁcation in cell culture
Complementary oligonucleotides corresponding to
non-sense mutations embedded in their natural context
(sequences in Table 1) were annealed and ligated into
the pAC99 dual reporter plasmid, as described earlier
(30). This dual reporter allows the quantiﬁcation of
stop-codon readthrough, thanks to the measurement of
luciferase and b-galactosidase (internal calibration)
activities, as previously described (11). The readthrough
levels of non-sense mutations were analyzed in the
presence or absence of gentamicin. NIH3T3 cells were
electroporated with 20mg of reporter plasmid and, the
following day, cells were rinsed and fresh medium, with
or without gentamicin, amikacin or G418 supplementa-
tion, was added. In these experiments, no cell toxicity
was observed for the doses of antibiotics used.
Table 1. p53 non-sense mutations
WT codon Mutation
a Sequence 50!30b Mutation frequency
c,%
TGG W53X GAT ATT GAA CAA TAG TTC ACT GAA 0.6
CAG Q144X ACC TGC CCT GTG TAG CTG TGG GTT 2.4
TGG W146X CCT GTG CAG CTG TGA GTT GAT TCC 4.3
CAG Q192X CTG GCC CCT CCT TAG CAT CTT ATC 4.1
CGA R196X CAG CAT CTT ATC TGA GTG GAA GGA 11.8
CGA R213X AGA AAC ACT TTT TGA CAT AGT GTG 14.5
GAG E298X GAG CCT CAC CAC TAG CTG CCC CCA 3.3
CGA R306X GGG AGC ACT AAG TGA GCA CTG CCC 7.7
CAG Q317X AGC TCC TCT CCC TAG CCA AAG AAG 1.3
TAT Y327X CTG GAT GGA GAA TAA TTC ACC CTT 0.1
CGA R342X TTC GAG ATG TTC TGA GAG CTG AAT 3.8
All mutations studied 49.6
aMutations are named by the position and the nature of the wild-type amino acid in p53 protein sequence.
bThese non-sense mutation sequences were inserted into the dual reporter vector in order to determine readthrough level.
cFrequencies were given relative to total non-sense mutations listed for p53 gene.
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with trypsin–EDTA (Invitrogen). b-Galactosidase and
luciferase activities were assayed as previously described
(30). The readthrough efﬁciency was estimated by
calculating the ratio of luciferase to b-galactosidase
activity obtained with the test construct and normalizing
it with respect to the ratio obtained with an in-frame
control construct. For each construct, at least ﬁve inde-
pendent transfection experiments were performed. For
readthrough quantiﬁcation in H1299 cells, the same
protocol was used, except that the Jet Pei method was
used for transfection. For each construct, at least three
independent transfection experiments were performed.
RNA extraction and quantitative PCR analysis
For the analysis of mRNA for p53 and its transcriptional
target genes, ASNS, Bax and p21, and APC, total RNA
was extracted from cells that had or had not been treated
with gentamicin (800mg/ml) or G418 (50 or 200mg/ml) for
72h (RNeasy Mini Kit, Qiagen) and subjected to DNAse I
digestion (RNase-free Dnase). RNA was quantiﬁed in a
Nanodrop apparatus (ThermoScientiﬁc) and the absence
of RNA degradation was conﬁrmed by agarose gel elec-
trophoresis. The ﬁrst-strand cDNA was synthesized from
2mg of total RNA, with random primers and the
SuperScript II Reverse Transcriptase (Invitrogen), as rec-
ommended by the manufacturer. Quantitative PCR was
then carried out on equal amounts of the various cDNAs,
with the thermoCycler CFX96 (Biorad), and the accumu-
lation of products was monitored with the intercalating
dye, FastStart Universal SYBRGreen Master (ROX)
reagent (Roche). We quantiﬁed mRNA levels relative to
three reference mRNAs: RPL32, Hprt1 and HMBS. In
each experiment, results are expressed relative to untreat-
ed cells, for which the value obtained was taken as 1.
Relative levels of gene expression were calculated using
conditions at the early stages of PCR, when ampliﬁcation
was logarithmic and could therefore be correlated with the
initial number of copies of the gene transcripts. The
speciﬁcity of quantitative PCR was checked by agarose
gel electrophoresis, which showed that a single product
of the desired length was produced for each gene. A
melting curve analysis was also performed. Single
product-speciﬁc melting temperatures were identiﬁed for
each gene. Oligonucleotides pairs used for ampliﬁcation
were described in Supplementary Data. For the quantiﬁ-
cation of each mRNA, three independent experiments
(from biological replicates) were performed in triplicate.
Western-blot analysis
HDQ-P1 cells (R213X) were treated with G418 (50, 100
and 200mg/ml) or gentamicin (800mg/ml) for 72h. The
medium was replaced and fresh antibiotics were added
each day. H1299 cells (p53-null) were transfected with
pCMVp53 wild-type, Q192X, R213X or E298X (30mg)
by the Jet Pei method (Ozyme). Each DNA precipitate
was dispensed into two 10mm plates, one of which was
left untreated and the other of which was immediately
treated with G418 (200mg/ml) for 48h. Cells were har-
vested by treatment with trypsin–EDTA (Invitrogen),
lysed in 350mM NaCl, 50mM Tris–HCl pH 7.5, 1%
NP-40, 1mM orthovanadate, 1mM NaF, 1mM PMSF
and protease inhibitor cocktail (Roche) and sonicated.
Total proteins were quantiﬁed with Bradford reagent
(Biorad) and extracts were denatured by incubation in
Laemmli buffer for 5min at 90 C. We subjected 20mgo f
total protein for HDQ-1 cells and 2–4mg of total protein
for H1299 cells to SDS–PAGE in NuPAGE Novex 4/12%
Bis–Tris pre-cast gels (Invitrogen). Proteins were
transferred onto nitrocellulose membranes, as recom-
mended by the manufacturer (Invitrogen). Membranes
were saturated by incubation for 1h in TBS containing
5% non-fat milk powder, and incubated with the
primary monoclonal antibody, DO-1 (N-terminal
epitope mapping between amino acid residues 11–25
of p53; Santa Cruz Biotechnologies, 1/400) or a monoclo-
nal antibody against mouse actin (Millipore, 1/2000).
After three washes in TBS containing 1% non-fat milk
powder, the membranes were incubated with the
secondary antibody [horseradish peroxidase-conjugated
anti-mouse IgG (1/ 2500) or alkaline phosphatase-
conjugated anti-mouse IgG (1/7000) Promega] for
45min. Six washes were performed and chemilumines-
cence was detected with ECL Western Blotting
Detection Reagents (Amersham, GE Healthcare) or
NBT/BCIP Tablets (Roche). The signal was quantiﬁed
with ImageQuant software.
Protein activity assays
We investigated the transcriptional activity of the p53
protein, using the p53BS-luc reporter plasmid containing
the ﬁreﬂy luciferase gene downstream from seven p53
binding sites.
For HDQ-P1 cells, which carry the endogenous p53
R213X non-sense mutation, antibiotics (G418 25, 50,
100 and 200mg/ml; gentamicin 800mg/ml; amikacin
2mg/ml) were added the day before transfection and on
each subsequent day. HDQ-P1 cells were cotransfected, by
the Jet Pei method, with p53BS-luc (2mg) and pCMVLacZ
(2mg). For each assay, DNA precipitates were dispensed
into two 6-well plates, one of which was treated with anti-
biotics and the other of which was not. Protein extracts
were prepared 72h after transfection, and enzymatic
activities were measured. Transfection with pCMVLacZ
was used to normalize transfection efﬁciency, cell viability
and protein extraction.
H1299 cells were cotransfected in the presence of the Jet
Pei reagent (Ozyme), as recommended by the manufactur-
er, with pCMVp53 WT or mutant constructs (3mg),
p53BS-luc (2mg) and pCMVLacZ (0.6mg). Antibiotics
(800mg/ml gentamicin, 50, 100 and 200mg/ml G418)
were added immediately after transfection. Protein
extracts were prepared 24h after transfection and
enzymatic activities were measured.
For each set of conditions, at least ﬁve independent
transfection experiments were performed.
siRNA transfections
The siRNAs used in this study double-stranded chemically
synthesized oligonucleotides provided by Thermo
3352 Nucleic Acids Research, 2011,Vol.39, No. 8Scientiﬁc. The siRNA targeting p53 is referred to as
3329-14-0020 and the non-targeting siRNA is referred to
as 1810-01-05. Transfection protocols were described in
Supplementary Data.
Flow cytometry analysis
H1299 cells were used to seed 6-well plates at a density of
1.4 10
5 cells per well and were then incubated for 48h.
The cells were transfected, in the presence of
Lipofectamine 2000 (Invitrogen), with pCMV p53 WT,
R213X or Q192X or pCMV empty (4mg), according to
the manufacturer’s instructions. G418 (200 or 400mg/ml)
was added immediately after transfection and the medium
was replaced the following day. We determined the
number of viable cells 48 hours after transfection, by
ﬂow cytometry (Guava Easycyte, Millipore) with the
ViaCount reagent (Millipore), as recommended by the
manufacturer. In this assay, a nuclear dye stained only
nucleated cells, whereas propidium iodide also stained
dying cells. The proportion of apoptotic cells was
determined with the Nexin reagent, which contains two
staining agents, Annexin V-PE and 7-AAD (Millipore),
as recommended by manufacturer. For each experiment,
at least four independent transfection experiments were
performed.
For each experiment, the percentage of cells expressing
p53 was estimated as described in Supplementary Data.
RESULTS
Identiﬁcation of p53 non-sense mutations responsive to
aminoglycoside treatment
We chose to study 11 non-sense mutations found in 50%
of cancer cells carrying a non-sense mutation in the p53
gene (UMD Database, all curated, October 2008). For
each non-sense mutation, the stop codon and the sur-
rounding nucleotide context, shown in Table 1, were
inserted into the dual reporter vector pAC99 (11,30).
Readthrough levels were quantiﬁed in NIH3T3 cells
transiently transfected with the dual reporter vector, in
the presence or absence of gentamicin (Figure 1A).
Readthrough rates ranged from 0.03% (p53 Y327X) to
0.5% (p53 R213X) for basal readthrough, and from
0.15% (p53 Y327X) to 2.8% (p53 R213X) in the
presence of 800mg/ml gentamicin. We also evaluated
the readthrough levels for each non-sense mutation in
Figure 1. Identiﬁcation of p53 nonsense mutations responsive to aminoglycoside treatment. (A) Readthrough efﬁciencies of 11 non-sense mutations
in the p53 gene were measured in NIH3T3 cells with and without gentamicin (800mg/ml) treatment for 24h. Three non-sense mutations (Q192X,
R213X and E298X) displayed levels of gentamicin-induced readthrough exceeding 0.5%. Mean values are presented together with the standard error
of the mean (SEM) (n=5). (B) Readthrough levels were measured for the nonsense mutations p53 Q192X, R213X and E298X in H1299 human
cancer cells in the presence of G418 (geneticin). Mean values are presented together with the standard error of the mean (SEM) (n=3).
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results obtained were similar to or lower than those
obtained with gentamicin (data not shown). Similar vari-
ations in basal readthrough levels and responsiveness to
aminoglycosides were reported in several previous studies
(28,31).
For further characterization, we focused on the R213X,
Q192X and E298X non-sense mutations, for which we
obtained the highest readthrough levels in the presence
of aminoglycosides. The R213X mutation is the most
frequent non-sense mutation in the p53 gene (14.5% of
reported non-sense mutations). For the three selected
non-sense mutations, we quantiﬁed the readthrough
levels obtained in the presence of G418 (geneticin),
because this antibiotic is the most potent readthrough
inducer among the aminoglycosides tested. All three
non-sense mutations displayed a dose-dependent
response to G418, resulting in readthrough levels greater
than those observed for gentamicin, reaching 6% for p53
R213X, the most responsive mutation (Figure 1B).
Aminoglycosides stabilize mutant p53 mRNA in cancer
cells carrying the endogenous non-sense mutation R213X
For further characterization, we focused on the human
HDQ-P1 cell line, which was established from a human
primary breast carcinoma (29). HDQ-P1 cells are
homozygous for the p53 R213X non-sense mutation,
which yielded the highest readthrough levels in the
presence of the various antibiotics tested. This mutation
is located in exon 6 and leads to the replacement of an
arginine residue by a premature UGA stop codon more
than 50nt upstream from the last exon–exon junction. The
mRNA molecule generated is thus entirely suitable for
degradation by the NMD pathway. Indeed, inhibition of
the NMD pathway by emetine, a potent and speciﬁc
inhibitor of NMD, increased the level of the mutant p53
R213X transcript by a factor of 11 in HDQP-1 cells
(Figure 2A).
The ability of readthrough event to antagonize NMD in
mammalian cells has been reported in several studies
(3,32,33). We therefore performed quantitative PCR on
HDQ-P1 cells with and without gentamicin or G418
treatment. The treatment of HDQ-P1 cells with gentami-
cin increased p53 R213X transcript levels by a factor of
four, whereas treatment with G418 led to an increase in
these levels by a factor of eight (Figure 3A). Higher
concentrations of G418 stimulate readthrough and
increase the accumulation of mutant mRNA. In the
LoVo cancer cell line, which carries a wild-type p53
gene, aminoglycoside treatment did not affect p53 tran-
script level (Figure 2B), demonstrating the dependence of
this effect on the presence of the non-sense mutation.
We then determined whether the effect of
aminoglycosides on the accumulation of a PTC-
containing mRNA was speciﬁc to transcripts targeted to
the NMD pathway. We used the LoVo cell line, which
carries the R1114X non-sense mutation in the
Adenomatous Polyposis Coli (APC) tumor suppressor
gene. This non-sense mutation is in the last exon and is
therefore unfavorable for mRNA degradation by the
NMD pathway. The quantiﬁcation of APC R1114X
mRNA in LoVo cells demonstrated that neither gentami-
cin nor G418 affected the amount of APC mRNA
(Figure 2C). Thus, aminoglycosides stabilize only
mRNAs with a PTC targeting them to the NMD pathway.
Aminoglycosides restore the production of full-length p53
protein from the endogenous non-sense mutation R213X
We investigated whether aminoglycosides could restore
the production of a full-length p53 protein from an en-
dogenous mutated gene, by treating the HDQ-P1 cell line
with gentamicin or G418. In the absence of treatment, we
detected a faint 30kDa band corresponding to the
expected truncated protein (Figure 3B). The weakness of
this signal was correlated with the low level of p53
mRNAs targeted to the NMD pathway (see above).
After G418 treatment, a 53kDa band corresponding to
the full-length protein was detected, the intensity of
which depended on the dose used. The amounts of
full-length protein were normalized with respect to those
in a cell line with WT p53 (LoVo cells). Full-length p53
levels reached 28, 56 and 85% those in LoVo cells with 50,
100 and 200mg/ml G418, respectively. Treatment with
gentamicin also led to the production of smaller, but
Figure 2. Readthrough of a nonsense mutation in an mRNA not targeted to NMD did not stabilize this transcript. Results are expressed relative to
the amount of mRNA in the absence of treatment. Quantitative PCR was used to determine mRNA levels. Mean values are presented together with
the standard error of the mean (SEM) (n=3). (A) Emetine treatment (25mg/ml for 10h) stabilizes non-sense-mutated p53 R213X mRNA in
HDQ-P1 cells. (B) Gentamicin (800mg/ml) or G418 (200mg/ml) does not stabilize a p53 WT mRNA in LoVo cells. (C) Gentamicin (800mg/ml)
or G418 (200mg/ml) does not stabilize the APC R1114X mRNA mRNA, which is not targeted to the NMD pathway in LoVo cells.
3354 Nucleic Acids Research, 2011,Vol.39, No. 8nonetheless signiﬁcant levels of full-length protein (18%).
Thus, aminoglycoside treatment restores the production
of a full-length p53 protein from an endogenous
mutated gene, in a dose-dependent manner, this effect
being proportional to the effect of the drug on
readthrough level. The additional band around 45kDa
observed in the WT lane might correspond to a degrad-
ation product or to one of the several isoforms that have
been described for human p53 protein (34).
Aminoglycoside treatment also triggered accumulation
of the truncated protein (Figure 3B). However, the differ-
ence in the increases achieved with 50 and 200mg/ml G418
were greater for the full-length protein (factor of 3) than
for the truncated form (factor of 1.6). This reﬂects the dual
effect of aminoglycoside treatment: inducing readthrough
(full-length protein) and stabilizing the transcript
(truncated and full-length proteins).
Aminoglycosides restore the production of full-length p53
proteins from two other non-sense mutants
No human cancer cell lines harboring the Q192X and
E298X p53 non-sense mutations, selected on the basis of
the high levels of readthrough achieved in the presence of
antibiotics, were available. We therefore investigated
whether aminoglycoside treatment led to the production
of a detectable full-length p53 protein from mutant
cDNA. We used the p53-null H1299 cell line, which was
derived from a non–small cell lung carcinoma and is
homozygous for a partial deletion of the p53 gene.
Western blot analysis were performed on protein
extracts from H1299 cells transiently transfected with
wild-type or mutant p53 expression vectors and left un-
treated or treated with G418 (Figure 4A). As a reference,
we also included the p53 R213X cDNA in these transient
transfection experiments. In cells transfected with the
Q192X, R213X or E298X construct, the bands detected
corresponded to the expected sizes of the truncated
proteins:  28,  30 and 40kDa, respectively.
For each mutation, G418 treatment also restored the
production of a full-length p53 protein. The amounts of
full-length protein detected after G418 treatment were 5.8,
44.2 and 5.4% those of the corresponding truncated form,
for p53 mutants Q192X, R213X and E298X, respectively.
Steady-state levels of full-length p53 were higher for the
R213X mutation, with which we obtained the highest level
of G418-induced readthrough. For this mutant, a 53kDa
full-length protein was detected even in the absence of
Figure 3. Effects of aminoglycoside treatment on the endogenous
non-sense mutation p53 R213X. (A) G418 and gentamicin stabilize
mutant p53 mRNA in HDQ-P1cells. HDQ-P1 cells carrying the en-
dogenous nonsense mutation R213X were treated with G418 (50 and
200mg/ml) or gentamicin (800mg/ml) for 72h and levels of mutant p53
mRNA were determined by quantitative PCR. The results of each
experiment are expressed relative to the quantity of mRNA in the
absence of treatment. Mean values are presented, together with the
SEM (n=3). (B) The full-length p53 protein is re-expressed after
aminoglycoside treatment. HDQ-P1 cells were left untreated ( )o r
were treated with G418 (50, 100 and 200mg/ml) or gentamicin
(800mg/ml) for 72h. Western-blot membranes were probed with the
DO-1 antibody directed against the N-terminus of p53 and a loading
control was performed with an anti-actin antibody. An extract from
LoVo cells (p53WT) was used as a control. (C) p53 transactivation
capacity is restored by the treatment of HDQ-P1 cells with
aminoglycosides. We assessed the transactivation capacity of the
full-length p53 proteins produced after aminoglycoside treatment,
using a reporter plasmid containing seven p53 binding sites upstream
from the ﬁreﬂy luciferase gene (p53BS-luc). We measured
p53-dependent luciferase activity in the presence or absence of G418
(50, 100 and 200mg/ml) or gentamicin (800mg/ml) for 96h and the
factor of increase of this activity is presented. As a control, HDQ-P1
cells were cotransfected with the p53BS-luc reporter plasmid and either
the p53-targeting siRNA (siRNA p53) or a non-targeting siRNA
(siRNA NT) and treated with G418 (200mg/ml). Mean values are pre-
sented together with the SEM (n=5). See Supplementary Data for
statistical analysis.
Nucleic Acids Research,2011, Vol.39, No. 8 3355antibiotic treatment (at levels  5.6% those for
the truncated form), probably due to a combination of
high basal readthrough levels and high levels of
expression.
Endogenous re-expressed p53 proteins recover their
transcriptional activity
The transactivation function of normal p53 protein under-
lies its function as a tumor suppressor gene. We
investigated whether the full-length p53 protein
produced after aminoglycoside treatment was an active
transcription factor, by transfecting HDQ-P1 cells (p53
R213X) with a reporter plasmid containing seven p53
binding sites upstream from the luciferase ﬁreﬂy gene
(p53BS-luc) and treating them with G418 or gentamicin.
In this context, an active p53 protein is required to induce
luciferase reporter gene expression. G418 treatment
strongly induced ﬁreﬂy luciferase expression, in a
dose-dependent manner, by a factor of up to 35 with
respect to basal levels. Treatment with gentamicin or
amikacin also increased p53-dependent ﬁreﬂy luciferase
expression, by a factor of up to ﬁve (Figure 3C and data
not shown). We checked that active p53 protein was
indeed responsible for the increase in ﬁreﬂy luciferase ex-
pression, using a siRNA speciﬁcally targeting p53 mRNA.
We ﬁrst checked the efﬁcacy of this siRNA, by assessing
its ability to decrease the levels of p53 mRNA generated
from a wild-type p53 expression vector in H1299 cells
(Supplementary Figure S1). We cotransfected cultures of
HDQ-P1 cells with the p53BS-luc reporter plasmid and
either the p53-targeting siRNA or a siRNA not targeting
the p53 mRNA and designed to have a minimal impact on
known human genes. In the presence of the p53-targeting
siRNA, the induction of luciferase expression by G418
was decreased by a factor of 2.3, whereas the
non-targeting siRNA had no signiﬁcant effect on the in-
duction of luciferase expression (Figure 3C). Thus, the
induction of luciferase activity by G418 is actually
mediated by p53.
Aminoglycosides also restore the transcriptional activity
of full-length p53 proteins produced from two other
non-sense mutants
We assessed the transcriptional activity of p53 proteins
re-expressed from the two other mutants, Q192X and
E298X, by cotransfecting H1299 cells with a pCMV
expression vector containing either the wild-type or a
mutant p53 cDNA, together with p53BS-luc (Figure 4B).
We included the R213X mutation in this experiment, for
comparison of the results obtained with those reported
above for the HDQ-P1 cell line. Transfection with the
wild-type p53 construct led to a high level of luciferase
activity, about 250 times higher than that observed after
transfection with the insert-less control vector. This level
was taken as 100% transactivation potential. In the
absence of treatment, luciferase activity induction for the
p53 mutants Q192X and R213X reached 0.6 and 2.5%,
respectively. This difference is consistent with the basal
readthrough level for the two mutations: 0.05 and 0.5%,
respectively (Figure 1A). Surprisingly, E298X gave a
residual luciferase activity of 18.5%. For the Q192X,
R213X and E298X mutants, G418 treatment induced
transcriptional activity in a dose-dependent manner,
reaching 47, 43 and 42%, respectively. Treatment with
gentamicin also induced p53 transcriptional activity, to a
lesser, but nonetheless signiﬁcant level, reaching 14, 17
and 25%, respectively. For conﬁrmation that the enhance-
ment of luciferase expression was mediated by p53
protein, we used the same siRNA strategy as described
above. In the presence of p53-targeting siRNA, the level
of induction of luciferase expression by G418 was 90%
lower than that in the absence of this siRNA, whereas a
siRNA not targeting p53 had no signiﬁcant effect on
luciferase expression (Figure 4B).
Aminoglycosides also rescued the transcriptional
activity of these three non-sense-mutated p53 proteins in
another type of human cancer cell, DLD-1 (colorectal
adenocarcinoma) cells, demonstrating that this effect
was not cell line-speciﬁc (Supplementary Figure S2).
Figure 4. Aminoglycosides restore the production and function of
full-length p53 proteins from p53 cDNA Q192X, R213X and E298X.
(A) Re-expression of full-length p53 proteins after 48h of G418 treat-
ment (200mg/ml) in H1299 cells transiently transfected with mutant p53
cDNA Q192X, R213X or E298X. Western-blot analysis was performed
with the DO-1 antibody directed against the N-terminus of p53.
(B) Aminoglycoside treatment restored p53 activity. The experiment
was carried out as in Figure 3C, except that luciferase activity is ex-
pressed as a percentage of the activity obtained with the wild-type p53
cDNA. Mean values are presented together with the SEM (n=5). See
Supplementary Data for statistical analysis.
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induced-readthrough (0.2%), failed to trigger a signiﬁcant
level of luciferase activity, although this activity increased
with G418 treatment (Supplementary Figure S3). Thus,
aminoglycoside treatment speciﬁcally rescues non-sense
p53 mutants with signiﬁcant induced readthrough levels.
Endogenous re-expressed full-length p53 proteins recover
their ability to regulate cellular target genes
We investigated whether the full-length p53 protein
produced after aminoglycoside treatments regulated en-
dogenous cellular target genes, by carrying out quantita-
tive PCR to assess differences in the expression of the
ASNS, Bax and p21 genes between HDQ-P1 cells with
and without G418 (200mg/ml) treatment. ASNS, an as-
paragine synthetase, is known to be down-regulated by
p53 (35) The Bax gene is a well characterized
pro-apoptotic gene and p21 is a cyclin-dependent kinase
inhibitor playing a crucial role in cell cycle control. Both
are up-regulated by p53. In each experiment, the results
obtained are expressed relative to untreated cells
(normalized to 1). For ASNS, transcript levels were 1.7
times lower in treated than in untreated cells (Figure 5A).
Levels of Bax and p21 mRNA in HDQ-P1 cells treated
with G418 were 1.9 and 12 times higher, respectively, than
those in untreated cells (Figure 5B and C). In these experi-
ments, none of the three references genes displayed a
change in mRNA level in response to G418 treatment.
Thus, the full-length p53 protein produced by
G418-induced readthrough was able to regulate the tran-
scription of three of its principally cellular gene targets,
with correct up- and down-regulation observed.
Re-expressed p53 full-length proteins recover their ability
to induce apoptosis
As p53 induces cell cycle arrest and initiates apoptosis, we
investigated whether the re-expression of an active,
full-length p53 protein following G418 treatment
affected these pathways in cultured human cancer cells.
We previously observed that HDQ-P1 cells, which carry
the endogenous p53 R213X non-sense mutation, were not
sensitive to the re-introduction of WT p53 (data not
shown). We therefore could not use this cell line to inves-
tigate the effects of G418 treatment on cell proliferation.
We thus assessed the effects of G418 on the induction of
p53-dependent growth inhibition in H1299 (p53
 / )
human cancer cells, which have been reported to be sen-
sitive to the re-expression of WT p53 (19). H1299 cells
were transfected with p53 WT, Q192X, R213X or empty
vector constructs and exposed to G418. Viable cells were
then counted by ﬂow cytometry, with the Viacount
reagent. Transfection with p53 WT resulted in numbers
of viable cells half those obtained after transfection with
an empty vector. However, viable cell number was not
affected by G418 treatment. For both non-sense p53
mutants, G418 treatment was associated with a decrease
in the number of viable cells from 9.5 10
5 cell/well
without treatment to 6 10
5 cells/well for the highest
dose of G418 (400mg/ml) (Figure 6A and Table 2). By
contrast, when H1299 cells were transfected with empty
vector, G418 treatment had no effect on cell number. An
analysis of the cell cycle gated on non-sense p53
mutant-transfected cells showed no effect of G418 treat-
ment on the cell cycle.
We then investigated whether G418-induced full-length
p53 protein promoted apoptosis in H1299 cells. For cells
transfected with the R213X or Q192X construct, percent-
ages of cells in early and late apoptosis were assayed by
ﬂow cytometry, with double staining (Nexin reagent, con-
taining 7-AAD and Annexin V-PE) (Table 2). In the
presence of the empty vector, the percentages of early
and late apoptotic cells were  15 and 9%, respectively,
reﬂecting the toxic effect of the transfection reagent itself.
Similar percentages were obtained for transfection with
the R213X and Q192X mutant p53 constructs, in the
absence of treatment. After G418 treatment, an increase
was observed in the percentages of both early ( 22%) and
late ( 20%) apoptotic cells, for both mutants, as shown in
Table 2. As a reference, transfection with the p53 WT
construct resulted in 22% of cells in early and 25% of
cells in late apoptosis. Thus, following G418 treatment,
re-expressed p53 proteins induced overall levels of
Figure 5. Full-length p53 proteins re-expressed after G418 treatment regulate cellular target genes. Quantitative PCR analysis was used to assess
differences in the levels of (A) ASNS, (B) Bax and (C) p21 mRNAs between HDQ-P1 (p53 R213X) cells with and without G418 (200mg/ml)
treatment for 72h. The results of each experiment are expressed relative to the amount of mRNA in the absence of treatment. Mean values are
presented with the SEM (n=3). See Supplementary Data for statistical analysis.
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(Figure 6B). In these experiments, the percentage of cells
expressing p53, as assessed with the DO-1 antibody and a
secondary FITC-conjugated antibody, was between 25
and 50%. Consequently, effects observed here are likely
to have been underestimated.
Thus, the treatment of cancer cells speciﬁcally express-
ing p53 Q192X or R213X with G418 decreased the
number of viable cells and increased the percentage of
cells undergoing apoptosis.
DISCUSSION
Several recent studies have demonstrated the potency of
readthrough-stimulating molecules for inducing the
production of full-length proteins from genes carrying a
PTC [reviewed in ref. (4,36)]. This approach has been
applied to several cell culture models of different
diseases, demonstrating the potential value of this
strategy for treating patients with genetic disorders
linked to the presence of a non-sense mutation. In
parallel, a few clinical trials have been performed on
DMD and CF patients, and some of these trials have
generated promising results (6–9). In this study, we
investigated whether aminoglycosides, a family of
readthrough-stimulating drugs, could be used to rescue
tumor suppressor genes altered by a non-sense mutation.
Only a few other studies have focused on this topic.
Keeling and Bedwell (37) have shown that
aminoglycosides can suppress non-sense mutations
within the p53 gene. However, although the results of
this study were encouraging, only one mutation was
tested in cell culture and the functionality of the
re-expressed protein was not assayed. More recently,
Zilberberg et al. (38) showed that antibiotics improved
clinical symptoms of tumorigenesis in a mouse model
carrying a non-sense mutation in the APC gene and in
xenografts of human cancer cells. However, the relation-
ship between the lower level of tumor development and
PTC readthrough was not established.
Figure 6. G418 induces apoptosis in a p53-dependent manner. H1299 cells transiently transfected with p53 Q192X, R213X, WT or empty vector
were left untreated or treated with G418 (200 and 400mg/ml) for 48h. (A) Cell numbers were determined by ﬂow cytometry with the Viacount
reagent. Mean values are indicated with the SEM (n=5) in Table 2. (B) Percentages of cells in early and late apoptosis were estimated by ﬂow
cytometry with Annexin-PE/7-AAD double-staining (Nexin reagent). The values shown are the percentages of cells in early and late apoptosis
(overall apoptosis). The percentages of cells in each category (early and late) with the SEM (n=4) are indicated in Table 2. See Supplementary Data
for statistical analysis.
Table 2. Number of viables cells and percentages of early and late apoptotic cells









WT 0 3.65±0.19 21.7±1.6 25.7±2.7 47.5±4.2
200 3.63±0.33 21.3±3.5 26.1±3.6 47.4±5.4
400 3.59±0.25 22.7±3.1 25.0±4.3 47.7±5.1
Empty vector 0 9.00±0.25 15.7±1.1 8.9±0.6 24.6±1.0
200 8.47±0.66 16.4±1.4 8.1±1.3 24.5±1.0
400 8.48±0.65 15.6±1.1 9.0±1.0 24.6±0.8
Q192X 0 8.67±0.27 15.0±1.0 10.1±1.0 25.2±1.7
200 6.12±0.19 19.6±1.4 13.2±1.1 32.8±1.9
400 5.17±0.26 22.2±1.3 19.0±0.2 41.1±0.6
R213X 0 9.05±0.47 17.8±0.9 11.1±0,8 28.9±1.6
200 6.22±0.39 20.7±0.9 14.7±1.0 35.5±1.8
400 5.45±0.57 24.1±1.3 21.4±2.3 45.5±3.1
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of the effect of aminoglycoside on an endogenous
non-sense mutation present in a human cancer cell line
and on two other mutations frequently observed in
cancers found in patients. We were able to decipher the
impact of aminoglycoside treatment on the whole gene
expression process including readthrough level, mRNA
stability, protein production and function and cell prolif-
eration. Our results strongly suggest that treating cancers
involving a PTC in a tumor suppressor gene is a realistic
new therapeutic approach.
Only a subset of p53 non-sense mutations is responsive to
readthrough inducers
Several factors determine the efﬁcacy of readthrough-
promoting molecules. The various stop codons are sup-
pressed with different efﬁciencies (UGA UAG >UAA),
and the efﬁcacy of suppression depends in part on the
identity of the +4 nucleotide immediately downstream
from the stop codon (C > U > A > G) (28,39,40). We
show here that, as for other genes, only a few p53
non-sense mutations are sensitive to antibiotic treatment.
Only three of the 11 PTC naturally occurring in the p53
gene display rates of gentamicin-induced readthrough
>0.5% (Figure 1A). This threshold was selected on the
basis of its being higher than the highest basal
readthrough level (p53 R213X). For these three muta-
tions, the+4nt is a C. However, other PTCs with a C in
this position present gentamicin-induced readthrough
rates below 0.5% (Q144X, Q317X).
Even moderate readthrough promotes the strong
stabilization of mutant mRNA
The amount of the mutant mRNA is another signiﬁcant
factor when using treatments to restore the production of
a full-length protein. Here, we observed that both G418
and gentamicin stabilized p53 mutant R213X mRNA in
cultured human HDQ-P1 cells (Figure 3A). We also
showed that mRNA stabilization was directly proportion-
al to the level of readthrough induced (Figure 1B). These
observations are very encouraging, because even moderate
levels of readthrough (2.8% for gentamicin and 6% for
G418) were sufﬁcient to counteract the induction of
mRNA degradation by the NMD pathway. These
ﬁndings are consistent with our previous data showing
that aminoglycoside induced readthrough, even if
modest, is able to antagonize the NMD pathway (37).
More generally, the capacity of readthrough-promoting
drugs to inhibit NMD has already been supported by
several reports (3,33,41). The mechanism by which sup-
pression events can interfere with NMD remains unclear.
Several studies have suggested that, in mammals, NMD is
triggered during the early round of translation and is
enhanced by the proteins of the EJC, located at each
exon–exon junction [reviewed in refs (42–44)]. One can
expect that if readthrough occurs at this early stage,
then the EJC protein complex is stripped off the mutant
transcripts, which are no longer targeted for NMD. We
cannot exclude a direct effect of aminoglycosides on
mRNA stabilization not mediated by PTC readthrough.
However, it has been shown in yeast that ura3 mRNA
stability altered by amber non-sense mutations is
restored when a UAG suppressor tRNA is added (45).
Keeling and his coworkers (46) also demonstrated, in
yeast, that readthrough above a threshold value of
 0.5% antagonizes NMD in the absence of any treat-
ment. Moreover several data indicate that for some
selenocystein mRNAs, an efﬁcient incorporation of
selenocystein by the Sec tRNA at UGA codons is
required to antagonize NMD (47,48). All these results
are in favor of a direct role of readthrough in the stabil-
ization of the mRNA by aminoglycoside treatment.
Whatever the case, the results presented here indicate
that a treatment protocol combining a readthrough
inducer and an NMD inhibitor would strongly potentiate
the production of a full-length protein.
Aminoglycosides induce the re-expression of full-length
active proteins
This treatment requires sufﬁcient amounts of mRNA to be
produced if it is to be effective. However, PTC
readthrough corresponds to the incorporation of a
near-cognate aminoacyl tRNA (complementary to two
of the three nucleotides of a stop codon), potentially re-
sulting in the replacement of the normal residue by an
amino acid incompatible with the stability or activity of
the full-length protein. In this study, the treatment of
HDQ-P1 cells carrying the genomic R213X p53
mutation with G418 or gentamicin led to the detection
of the full-length protein (Figure 3B). The amount of
re-expressed p53 protein was proportional to the
readthrough level. For the highest dose of G418,
full-length protein levels were similar to those in a cell
line producing wild-type p53.
We next showed, with a reporter plasmid carrying p53
binding sites upstream from a luciferase gene, that the p53
protein re-expressed in HDQ-P1 cells had recovered its
transcriptional activation properties (Figure 3C).
Moreover, this full-length p53 protein was able to up-
and down-regulate three of its known cellular target
genes (Figure 5). The up-regulated Bax gene is involved
in the apoptosis pathway, the up-regulated p21 gene
encodes a cyclin-dependent kinase inhibitor playing a
crucial role in cell cycle control and ASNS encodes an
asparagine synthetase that is down-regulated by p53.
Thus, both the quantity and the quality of the full-length
p53 protein induced by G418 treatment were compatible
with the appropriate regulation of targeted genes.
We also tested other p53 mutants for which no mutant
cell lines were available, in a transient transfection assay
with cDNA. These experiments also showed that the
re-expressed p53 protein recovered its transactivation
activity in a dose-dependent manner upon G418 treatment
(Figure 4B). This activity reached  45% that of the
wild-type p53. However, Q192X had the same transacti-
vation potential as R213X despite having only one-ﬁfth its
readthrough efﬁciency. This suggests that the amino acids
incorporated at the stop codon may have different effects
on protein activity. In the case of p53 Q192X, the amino
acids incorporated after aminoglycoside treatment result
Nucleic Acids Research,2011, Vol.39, No. 8 3359in full p53 activity, whereas, for p53 R213X, at least some
of the incorporated amino acids may result in lower levels
of activity.
We have recently obtained preliminary results showing
that aminoglycoside treatment can also rescue the activity
of APC tumor suppressor gene carrying a PTC
(C. Floquet, J.-P. Rousset and L. Bidou, unpublished
data). Thus, this approach may be applicable to a large
proportion of cancers.
Recovering tumor suppressor function
We then analyzed the effect of re-expressed p53 on cell
cycle progression and apoptosis in H1299 cancer cells
transiently expressing p53 Q192X or R213X. We choose
this cell model because it is sensitive to the reintroduction
of p53 WT. We ﬁrst demonstrated that, in presence of
G418, cultures re-expressing p53 contain only 50% as
many viable cells as untreated cells (Figure 6A). This
effect was very evident and pronounced despite only a
proportion of the cells being transfected. We therefore
might expect this effect to be ampliﬁed in a population
in which all the cells carried an endogenous PTC. We
then determined the respective roles of cell cycle arrest
and apoptosis in this diminution. Indeed, induction of
the p53 tumor suppressor protein in deﬁcient cells may
lead to either cell cycle arrest or apoptosis, but the mech-
anisms leading to one or other of these responses being
elicited in a given cell remain unclear. Cell type appears to
be one of the factors involved in this process, together
with p53 levels, with low levels resulting in cell cycle
arrest whereas high levels seem to direct apoptosis (19).
We observed no signiﬁcant disturbance in cell cycle, but
there was a clear impact on the number of apoptotic cells,
which were identiﬁed on the basis of their ability to bind
Annexin V, a ligand of Phosphatidyl Serine speciﬁcally
externalized early in the apoptosis pathway (Figure 6B).
These data may reﬂect a preferential triggering of the
apoptotic pathway due to the high level of
G418-induced p53 expression in the population of trans-
fected cells. However, we cannot rule out the possibility
that p53 also induced cell cycle arrest in a manner not
detectable in the model used here. Whatever the actual
situation, these results demonstrate that readthrough
inducers can be used to limit cancer cell growth.
Therapeutic use of readthrough inducers
Gentamicin, commonly used to treat bacterial infections
in clinical care, displays nephrotoxicity and ototoxicity
that might restrict its long-term use (49,50). This could
be a serious problem if we need to apply this type of
PTC therapy to classical genetic disorders, which would
require lifetime treatment. However a six-month course of
gentamicin treatment in DMD patients was recently
completed safely, with no impairment of renal or
hearing function (10). As previously reported, G418
stimulates readthrough more efﬁciently than gentamicin,
but high doses are toxic in cultured cells. The toxicity of
this drug to humans is unknown, but its structural simi-
larity to gentamicin suggests that similar restrictions may
apply to chronic treatment. However, this molecule has
been shown to be very potent in a mouse model of
non-sense mutation bypass, at doses inducing no adverse
effects (51). A certain level of toxicity is acceptable for
anticancer drugs, which are used for relatively short
periods of time and may signiﬁcantly improve what
would otherwise be a severe, untreatable disease.
Furthermore, several strategies have recently emerged
for preventing gentamicin toxicity by targeting megalin,
the receptor for these compounds on the cell (52,53).
Moreover, new derivatives of geneticin with enhanced
stop suppression ability and lower cell toxicity are current-
ly being developed (54). With the exception of
aminoglycosides, only a few compounds are known to
promote readthrough. This is the case for the antibiotic
negamycin and the recently identiﬁed compound PTC124.
PTC124 has been described to induce re-expression of full
length protein in mouse model of Duchenne muscular dys-
trophy (55) and CF (56). This compound is thought to act
in a fashion that is distinct from aminoglycoside and to
present fewer side effects than gentamicin. PTC124 is cur-
rently being evaluated in clinical trials for the treatment of
hemophilia and CF [(57,58), and information obtained
from ClinicalTrials.gov], and its effects on the
re-expression of tumor suppressor genes may also be
evaluated.
It should be noted that readthrough-inducing treat-
ments may also trigger the accumulation of a truncated
form of the protein, as illustrated here (Figure 3B). This
results from the stabilization of the mRNA, allowing the
production of both the truncated and full-length proteins.
Therapeutic approaches based on promoting readthrough
should thus take into account the potential deleterious
effect of truncated proteins, which may have a
dominant-negative effect. However, truncated forms of
p53 would be likely to lack the nuclear localization
signal and the tetramerization domain located at the
C-terminus of the protein, and would therefore be
unable to interact with the re-expressed full-length p53.
In summary, these results provide evidence that the
treatment of cancer cells carrying a PTC in the p53 gene
with aminoglycosides results in the re-expression of sufﬁ-
cient functional protein to affect cell viability. These
ﬁndings may lead to the development of new strategies
for treating any type of cancer involving the presence of
a PTC in a tumor suppressor gene, and will also help to
broaden the existing range of treatments for cancer.
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